New advances in prostate cancer diagnosis: Outcomes from the 2022 Panjiayuan Consensus Conference

The 2022 Panjiayuan Consensus Conference, held by the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, has introduced pivotal advancements in prostate targeted biopsy (TB) strategies and development, marking a significant leap forward in the diagnosis and management of prostate cancer (PCa).

Prostate cancer remains one of the most significant health challenges worldwide, with the need for precise diagnosis more critical than ever. Traditional systematic biopsy methods are being complemented by targeted biopsy techniques, which are proving to be more effective in detecting clinically significant prostate cancer. This shift comes as imaging technologies and biopsy techniques rapidly evolve, requiring updates to existing protocols and practices.

In a consensus published in the journal of UroPrecision, the conference outlined ten key areas for prostate biopsy, including imaging selection, TB indications, and biopsy techniques. High-quality evidence now supports the use of targeted biopsy over traditional methods due to its higher rate of detecting clinically significant cancer. Experts reviewed 14 critical questions through anonymous voting, reflecting a consensus based on clinical practice rather than just empirical evidence. The outcomes suggest a move towards integrated diagnostic pathways combining traditional and targeted methods to enhance detection rates and reduce unnecessary interventions.

Dr. Gang Song, lead researcher and co-author of the study, emphasized, "The consensus achieved at the conference reflects our commitment to enhancing the precision of prostate cancer diagnostics. The collaborative effort has culminated in a set of refined strategies that prioritize patient safety and diagnostic accuracy."

The 2022 Panjiayuan Consensus Conference has set a new standard in prostate cancer diagnosis, emphasizing targeted biopsy techniques supported by cutting-edge imaging technologies. With targeted biopsy, clinicians can achieve more accurate diagnoses, reducing the number of unnecessary biopsies and associated complications. These developments promise to significantly impact the diagnostic landscape, offering patients more precise and less invasive diagnostic options and paving the way for tailored therapeutic strategies.

###

References

DOI

10.1002/uro2.18

Original Source URL

https://doi.org/10.1002/uro2.18

About UroPrecision

UroPrecision is an open access urology journal. UroPrecision publish the latest, practical, timely, and cutting-edge content on investigations and treatment of urological diseases to physicians and researchers practicing precision urology worldwide. Coverage spans diverse medical disciplines, including oncology, endocrine gland diseases and metabolic diseases, artificial intelligence, medical imaging, biomedical engineering, robotic surgery, and clinical research.